Unintentional combining enzalutamide with a moderate CYP2C8 inhibitor in a patient with metastatic castration-resistant prostate cancer: a case report.

S H VerhulstEmmy BoerrigterS RasN P van ErpP Hamberg

Published in: Cancer chemotherapy and pharmacology (2022)

This case report shows that enzalutamide can be safely prescribed while cotreated with a moderate CYP2C8-inhibitor, without reducing the dose. More research is warranted to make a statement about the effect of enzalutamide on clopidogrel.

Keyphrases

prostate cancer
case report
high intensity
acute coronary syndrome
small cell lung cancer
squamous cell carcinoma
percutaneous coronary intervention
antiplatelet therapy